SAR439859
Total Payments
$1.3M
Transactions
187
Doctors
13
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.2M | 98 | 10 |
| 2018 | $117,358 | 70 | 4 |
| 2017 | $6,187 | 19 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 161 | 98.2% |
| Consulting Fee | $21,849 | 14 | 1.7% |
| Travel and Lodging | $1,226 | 7 | 0.1% |
| Food and Beverage | $158.19 | 5 | 0.0% |
Payments by Type
Research
$1.3M
161 transactions
General
$23,233
26 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Wom | SANOFI US SERVICES INC. | $589,241 | 0 |
| A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer | SANOFI US SERVICES INC. | $523,741 | 0 |
| An Open Label Randomized Phase 2 Trial of SAR439859, Versus Endocrine Monotherapy as Per Physician's Choice in Premenopausal and Postmenopausal Patients With Estrogen Receptor-positive, HER2-Negative | SANOFI US SERVICES INC. | $118,616 | 1 |
| Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer | SANOFI US SERVICES INC. | $14,154 | 1 |
| A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal wom | SANOFI-AVENTIS U.S. LLC | $6,318 | 4 |
| Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | SANOFI US SERVICES INC. | $2,310 | 0 |
| Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer | SANOFI-AVENTIS U.S. LLC | $1,817 | 4 |
| Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC) | SANOFI-AVENTIS U.S. LLC | $1,590 | 4 |
Top Doctors Receiving Payments for SAR439859
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $1.2M | 135 |
| , MD | Hematology & Oncology | Guaynabo, PR | $28,308 | 2 |
| , M.D. PH.D | Diagnostic Radiology | Los Angeles, CA | $19,156 | 17 |
| , MD | Medical Oncology | Boston, MA | $4,162 | 7 |
| , M.D., PH.D | Medical Oncology | New York, NY | $2,431 | 6 |
| Hannah Linden | Medical Oncology | Seattle, WA | $2,431 | 6 |
| , M.D | Internal Medicine | Palo Alto, CA | $2,012 | 3 |
| , MD | Internal Medicine | Boston, MA | $1,457 | 2 |
| , MD | Hematology & Oncology | Tampa, FL | $1,150 | 4 |
| , MD | Medical Oncology | Fairfield, IA | $43.47 | 1 |
| , M.D | Hematology & Oncology | Chicago, IL | $28.68 | 1 |
| , M.D | Pain Medicine | Brooklyn, NY | $28.68 | 1 |
| , MD | Medical Oncology | Houston, TX | $28.68 | 1 |
| , MD | Family Medicine | Anderson, SC | $28.68 | 1 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $1.2M
- SANOFI-AVENTIS U.S. LLC $32,958
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 13
- Transactions 187
About SAR439859
SAR439859 is a drug associated with $1.3M in payments to 13 healthcare providers, recorded across 187 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $1.2M was paid across 98 transactions to 10 doctors.
The most common payment nature for SAR439859 is "Unspecified" ($1.3M, 98.2% of total).
SAR439859 is associated with 8 research studies, including "A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Wom" ($589,241).